XLV241227C130000
- 0.00
- 0.000.00%
The Health Care Select Sector SPDR® Fund Newsroom
Unpacking the Latest Options Trading Trends in UnitedHealth Group
This Omeros Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
ResMed, Inspire Medical Fall After Lilly's Zepbound Gains Sleep Apnea Indication
2024's 'Biggest Loses' That Could See Reversal in 2025
Danaher Analyst Ratings
Thermo Fisher Scientific Analyst Ratings
Sector Update: Health Care Stocks Fall Premarket Monday
ETF Shorts Were up Last Week, Led by Large-cap ETFs
Leading And Lagging Sectors For December 23, 2024
Exchange-Traded Funds, Equity Futures Mixed Pre-Bell Monday as Investors Assess Fed's Interest Rate Outlook
SA Asks: Which Big Pharmas Are Likely to Announce Big M&A Deals?
Big Biopharma Trails Behind The Market: JP Morgan's 2025 Outlook on Eli Lilly, Merck, and More
Materials, Software Stocks Are Best Poised for H1 Outperformance: Goldman Sachs
Eli Lilly's Zepbound Receives FDA Approval For Obesity-Linked Sleep Apnea Drug
Eli Lilly and Co's Zepbound has been approved by the FDA for the treatment of obstructive sleep apnea.
① The FDA in the USA approved Eli Lilly and Co's weight loss medication Zepbound on Friday for the treatment of obstructive sleep apnea (OSA), making it the first drug approved for directly treating this common sleep disorder; ② The active ingredient in Zepbound is Tirzepatide, which was initially used to treat type 2 diabetes, namely Eli Lilly and Co's Mounjaro.
Wall Street Suffers Worst Week in Over a Month After Fed Delivers a Reality Check
Trending Stocks in Bearish Pre-holiday Week for U.S. Stock Market
Novo Nordisk Raises Expectations for Eli Lilly After CagriSema Slipup
Did Novo-Nordisk A/S fall, leaving Eli Lilly and Co to dominate the weight loss medication market?
Novo-Nordisk A/S faced a "Waterloo," with new drug effects falling short of expectations, causing a dramatic drop in stock prices. The landscape of the weight loss drug market is quietly changing; will Eli Lilly and Co become a sole oligopoly?
The Health Care Select Sector SPDR Fund To Go Ex-Dividend On December 23rd, 2024 With 0.62165 USD Dividend Per Share